Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ease of Use and Safety of U300 Insulin Glargine Pen Injector in Insulin-Naïve Type 2 Diabetes Mellitus Patients
2014-001253-16Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of insulin glargine U300 in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Primary endpoint: Ease-of-use / ease of learning questionnaire. Started Jun 2014; status: completed.
02
Drugs
insulin glargine U300
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2014-001253-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001253-16.